Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, comments on the use of measurable residual disease (MRD) to personalize therapy for patients with multiple myeloma, mentioning key clinical trials including RADAR (ISRCTN46841867; UK-MRA Myeloma XV), and explaining how MRD status may be used in the future to de-escalate therapy, define duration of maintenance therapy, initiate treatment before disease relapse, and to change treatment for high-risk patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.